These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 28240681)

  • 21. Long-term efficacy of neoadjuvant-adjuvant targeted therapy in borderline resectable stage IIIB-D and IV melanoma.
    Czarnecka AM; Ostaszewski K; Błoński PJ; Szumera-Ciećkiewicz A; Świtaj T; Kozak K; Koseła-Patreczyk H; Rogala P; Kalinowska I; Zaborowski K; Krotewicz M; Borkowska A; Rutkowski P
    Cancer; 2024 Oct; 130(20):3463-3472. PubMed ID: 38843386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Melanoma: BRAFi Rechallenge.
    Kosmidis CS; Papadopoulou K; Mystakidou CM; Papadopoulou E; Mantalovas S; Varsamis N; Koulouris C; Theodorou V; Papadopoulos K; Sevva C; Miltiadous P; Petanidis S; Georgakoudi E; Papadopoulou E; Baka S
    Medicina (Kaunas); 2023 May; 59(5):. PubMed ID: 37241207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series.
    Carlino MS; Vanella V; Girgis C; Giannarelli D; Guminski A; Festino L; Kefford RF; Menzies AM; Long GV; Ascierto PA
    Br J Cancer; 2016 Nov; 115(11):1280-1284. PubMed ID: 27711085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Baseline neutrophil-to-lymphocyte ratio (NLR) is associated with outcome of patients treated with BRAF inhibitors.
    Cocorocchio E; Martinoli C; Gandini S; Pala L; Conforti F; Stucchi S; Mazzarol G; Ferrucci P
    Clin Transl Oncol; 2020 Oct; 22(10):1818-1824. PubMed ID: 32108276
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined therapy with dabrafenib and trametinib in BRAF-mutated metastatic melanoma in a real-life setting: the INT Milan experience.
    Cavalieri S; Di Guardo L; Cimminiello C; Bono A; Tolomio E; Colombetti A; Valeri B; Di Tolla G; de Braud F; Del Vecchio M
    Tumori; 2016 Oct; 102(5):501-507. PubMed ID: 27470608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600-mutated melanoma.
    Amann VC; Hoffmann D; Mangana J; Dummer R; Goldinger SM
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1638-1640. PubMed ID: 28401596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
    Seeley AR; De Los Santos JF; Conry RM
    Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/β-catenin signaling.
    Chien AJ; Haydu LE; Biechele TL; Kulikauskas RM; Rizos H; Kefford RF; Scolyer RA; Moon RT; Long GV
    PLoS One; 2014; 9(4):e94748. PubMed ID: 24733413
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment.
    Cassidy MR; Wolchok RE; Zheng J; Panageas KS; Wolchok JD; Coit D; Postow MA; Ariyan C
    EBioMedicine; 2017 Apr; 18():56-61. PubMed ID: 28356222
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors.
    Amaravadi RK; Hamilton KE; Ma X; Piao S; Portillo AD; Nathanson KL; Carlino MS; Long GV; Puzanov I; Xu X; Morrissette JJ; Tsai KY; Flaherty KT; Sosman JA; Goodman GR; McArthur GA; Rustgi AK; Metz DC; Schuchter LM; Chapman PB; Sepulveda AR
    Clin Cancer Res; 2015 Dec; 21(23):5215-21. PubMed ID: 26202952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma.
    Amini-Adle M; Khanafer N; Le-Bouar M; Duru G; Dalle S; Thomas L
    BMC Cancer; 2018 Jul; 18(1):705. PubMed ID: 29970025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRAF inhibitor rechallenge in patients with advanced BRAF V600-mutant melanoma.
    Roux J; Pages C; Malouf D; Basset Seguin N; Madjlessi N; Baccard M; Comte C; Archimbaud A; Battistella M; Viguier M; Mourah S; Bagot M; Lebbe C
    Melanoma Res; 2015 Dec; 25(6):559-63. PubMed ID: 26397052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
    Sanlorenzo M; Choudhry A; Vujic I; Posch C; Chong K; Johnston K; Meier M; Osella-Abate S; Quaglino P; Daud A; Algazi A; Rappersberger K; Ortiz-Urda S
    J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High baseline neutrophil-to-lymphocyte ratio predicts worse outcome in patients with metastatic BRAF-positive melanoma treated with BRAF and MEK inhibitors.
    Teterycz P; Jagodzińska-Mucha P; Cybulska-Stopa B; Mariuk-Jarema A; Kozak K; Koseła-Paterczyk H; Czarnecka AM; Rajczykowski M; Dziura R; Galus Ł; Mackiewicz J; Świtaj T; Klimczak A; Falkowski S; Suwiński R; Ziobro M; Ługowska I; Rutkowski P
    Melanoma Res; 2018 Oct; 28(5):435-441. PubMed ID: 29782381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.
    Menzies AM; Wilmott JS; Drummond M; Lo S; Lyle M; Chan MM; Thompson JF; Guminski A; Carlino MS; Scolyer RA; Kefford RF; Long GV
    Cancer; 2015 Nov; 121(21):3826-35. PubMed ID: 26218930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.
    Dummer R; Goldinger SM; Turtschi CP; Eggmann NB; Michielin O; Mitchell L; Veronese L; Hilfiker PR; Felderer L; Rinderknecht JD
    Eur J Cancer; 2014 Feb; 50(3):611-21. PubMed ID: 24295639
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma-A Retrospective Multicenter ADOReg Study.
    Stege H; Haist M; Schultheis M; Fleischer MI; Mohr P; Meier F; Schadendorf D; Ugurel S; Livingstone E; Zimmer L; Herbst R; Pföhler C; Kähler K; Weichenthal M; Terheyden P; Nashan D; Debus D; Kaatz M; Ziller F; Haferkamp S; Forschner A; Leiter U; Kreuter A; Ulrich J; Kleemann J; Bradfisch F; Grabbe S; Loquai C
    Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34065877
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes.
    Lee J; Ahmed T; Maurichi A; Di Guardo L; Stagno AM; Warburton L; Taylor AM; Livingstone E; Rehman S; Khattak A; Kahler KC; Vanella V; Atkinson V; Millward M; Schadendorf D; Johnson DB; Ascierto PA; Hauschild A; Lo SN; Long GV; Menzies AM; Carlino MS
    Eur J Cancer; 2023 Jan; 179():87-97. PubMed ID: 36509002
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination therapy targeting the elevated interleukin-6 level reduces invasive migration of BRAF inhibitor-resistant melanoma cells.
    Mohapatra P; Prasad CP; Andersson T
    Mol Oncol; 2019 Feb; 13(2):480-494. PubMed ID: 30582770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma.
    Park JJ; Hawryluk EB; Tahan SR; Flaherty K; Kim CC
    JAMA Dermatol; 2014 Mar; 150(3):307-11. PubMed ID: 24352115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.